

Consolidated Financial Statements of

BIONOID, INC.

March 31, 2022 and 2021

MANAGEMENT'S COMMENTS ON UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

NOTICE OF NO AUDITOR REVIEW OF FINANCIAL STATEMENTS

The accompanying unaudited condensed consolidated financial statements of Bionoid, Inc. (the "Company") have been prepared by and are the responsibility of the Company's management. The unaudited condensed consolidated financial statements are prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS") and reflect management's best estimates and judgment based on information currently available. The Company's independent auditor has not performed a review of these unaudited condensed consolidated financial statements.

BIONOID, INC.
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS OF FINANCIAL POSITION (UNAUDITED)
Expressed in U.S. Dollars

	March 31, 2022	December 31, 2021
Assets		
Current assets		
Cash and cash equivalents	\$ 5,995	\$ 7,260
Property, plant and equipment	28,340	1,473
Accounts receivable	13,955	41,756
Patents, trademarks	21,185	21,185
Investment in shares	-	-
Total current assets	69,475	71,674
Total assets	\$ 69,475	\$ 71,674
Liabilities and shareholders' equity		
Current liabilities		
Loans payable	\$ 133,652	\$ 133,652
Accounts payable	588	9,049
Other current liabilities	11,262	-
Total current liabilities	145,502	140,605
Total liabilities	\$145,502	\$142,701
Shareholders' equity		
Contributed surplus	19,184,218	19,117,093
Shareholders' contribution	9,570	9,560
Accumulated deficit	(20,718,882)	(20,646,497)
Common stock	1,449,067	1,448,817
Total shareholders' equity	(76,027)	(71,027)
Total liabilities and shareholders' equity	69,475	71,674
On behalf of the Board:		

(signed) "Wayne Cockburn"
Director

BIONOID, INC.

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(UNAUDITED)

Expressed in U.S. Dollars

	Quarter ended March 31, 2022	Quarter ended March 31, 2021
Revenue		
Gross sales	\$ 17,447	65,432
Less Cost of sales	(14,594)	(27,168)
Gross profit before operating expenses	2,853	38,264
Operating expenses		
Dues and subscriptions	315	342
Office expenses	7,650	315
Professional fees	159	600
Other expenses	50	3,419
	8,174	33,588
Gross income (loss)	\$ 8,174	\$ 33,588
Net income (loss)	\$ (5,321)	\$ 33,588

BIONOID, INC.
CONDENSED CONSOLIDATED INTERIM STATEMENT OF CHANGES IN EQUITY (UNAUDITED)
Expressed in U.S. Dollars

	Capital Stock (Number of Shares)	Capital Stock (\$)	Contributed Surplus	Deficit	Total Shareholder's Equity (Deficit)
Balance, December 31, 2020	38,358	\$ 1,443,522	\$ 19,085,761	\$ (20,579,745)	\$ (40,902)
Balance, March 31, 2021	38,358	\$ 1,443,522	\$ 19,085,761	\$ (20,546,157)	\$ 473,686
Shares issued for employment agreements	5,440,412	544	9,383		
Shares issued for distribution agreement	41,803,126	4,180	72,097		
Shares issued upon conversion of debt	5,712,714	571	9,852		
Balance, September 30, 2021	52,994,610	\$ 1,448,817	\$ 19,177,093	\$ (20,570,091)	\$ 780
Shares issued for employment agreements	1,000,000	100	1,725		
Balance, December 31, 2021	53,994,610	\$ 1,448,917	\$ 19,178,818	\$ (20,646,497)	\$ 780
Shares issued for employment agreements	1,500,000	150	5,400		
Balance, March 31, 2022	55,494,610	\$ 1,449,067	\$ 19,184,218	\$ (20,718,882)	\$ (76,027)

BIONOID, INC.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (UNAUDITED)
Expressed in U.S. Dollars

	<u>Mar. 31, 2022</u>	<u>Dec. 31, 2021</u>
Beginning Cash Balance	\$ 7,260	\$ 630
Cash Flows from Operating Activities		
Net Profit (Loss)	(5,321)	(21,274)
Adjustments to Reconcile Net Income to Net Cash		
Increase in Accounts Receivable	(27,801)	41,756
Increase in Accounts Payable	8,461	(9,049)
Increase in Customer Deposits	0	0
Amortization	0	0
Gain (Loss) on Sale of Stock	0	0
Total Cash Inflows	11,433	11,433
Net Cash From Operating Activities	\$ (17,401)	\$ 11,433
Cash Flows from Operating Activities		
Loan Borrowings	0	0
Proceeds from Sale of Stock	0	0
Accounts payable	0	0
Customers deposits	0	0
Total Cash Inflow	\$ 0	\$ 0
Net Increase (Decrease) in Cash	\$ (17,401)	\$ 11,433
Ending Cash Balance	\$ 5,995	\$ 7,260